Skip to main content

Semaglutide (Investigational)

07-14-2023 | Type 2 diabetes | News

Cagrilintide plus semaglutide shows dual benefit in type 2 diabetes

Improved glycemic control and weight loss seen with the coadministration of cagrilintide and semaglutide in a phase 2 trial.

01-09-2023 | Semaglutide | News

FDA approves high-dose semaglutide for adolescents with obesity

Read more about this decision here

12-01-2022 | Semaglutide | News

High-dose semaglutide reduces obesity-linked inflammatory marker

Levels of the inflammatory marker C-reactive protein decrease in people with or without type 2 diabetes taking weekly semaglutide 2.4 mg, shows analysis of three STEP trials.

11-02-2022 | Semaglutide | News

STEP TEENS: High-dose semaglutide weight loss benefits shown in adolescents

Semaglutide at a dose of 2.4 mg/week results in substantial weight loss among adolescents with obesity, show the results of the STEP TEENS trial.

Doctor measures a man's waist

10-10-2022 | Semaglutide | News

STEP 5: Sustained semaglutide treatment maintains weight loss

The substantial weight loss achieved with weekly semaglutide 2.4 mg is maintained if people continue to take the medication for 2 years, show the STEP 5 results.

05-19-2022 | Semaglutide | News

Semaglutide offers alternative to prandial insulin in type 2 diabetes

Adding a weekly semaglutide injection in people already using basal insulin to treat type 2 diabetes avoids the need for prandial insulin, show the SUSTAIN 11 findings.

05-09-2022 | Semaglutide | News

Bodyweight rebounds after semaglutide withdrawal

People who lose weight while taking semaglutide 2.4 mg regain two-thirds of what they lost during the first year after stopping the medication, shows the STEP 1 extension study.

04-08-2022 | DUKPC 2022 | Conference coverage | News

Within-class switch to semaglutide brings benefits in real-world cohort

Real-world data confirm glycated hemoglobin and weight benefits, albeit attenuated, for people with type 2 diabetes switching to injectable semaglutide from other GLP-1 receptor agonists.